JRF 401
Alternative Names: JRF-401Latest Information Update: 28 Jun 2025
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Psoriasis in China
- 28 Jun 2025 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China
- 22 Jun 2023 Preclinical development for Rheumatoid arthritis and Psoriasis is ongoing in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, June 2023)